This is a working overview of clinical development, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
== Properties and structure == Thiophene is a colorless liquid at room temperature. The high reactivity of thiophene toward sulfonation is the basis for the separation of thiophene from benzene, which are difficult to separate by distillation due to their similar boiling points (4 °C difference at ambient pressure). Like benzene, thiophene forms an azeotrope with ethanol. The molecule is flat; the bond angle at the sulfur is around 93°, the C–C–S angle is around 109°, and the other two carbons have a bond angle around 114°. The C–C bonds to the carbons adjacent to the sulfur are about 1.34 Å, the C–S bond length is around 1.70 Å, and the other C–C bond is about 1.41 Å.
By contrast, the Biden administration's 2022 Review, while prioritizing Ground-based Midcourse Defense, emphasized that it is "neither intended nor capable of defeating" peer-level threats from Russia or China, noting "the interrelationship between strategic offensive arms and strategic defensive systems." While terrestrial defenses developed, the vision of a full space-based shield remained a consistent goal for its proponents. The modern groundwork for the Golden Dome was laid in 2017 by the SDI's former Deputy of Technology, and prominent Team B leader, Michael D. Griffin, who formed the Space Development Agency during the first Trump administration. Griffin long advocated for reusable launch vehicles to make the mass launching of weapons into space economically feasible. While the original Strategic Defense Initiative's attempts at this were short-lived, with the DC-X failing after a series of test flights, Griffin later encouraged and promoted funding of commercial reusable launch vehicles, which have since proven successful. The Heritage Foundation's Project 2025 effort advocated for a Golden Dome-like effort, writing that SpaceX's development of Starlink proves the feasibility of a space-based "overlayer" of thousands of networked satellites and interceptors, broadly similar to the Brilliant Pebbles concept of the 1980s. During his 2024 presidential campaign, Trump repeatedly mentioned the missile shield concept, often to mixed reception.
=== Transfer RNA modifications === Transfer RNA or tRNA is the most abundantly modified type of RNA. Modifications in tRNA play crucial roles in maintaining translation efficiency through supporting structure, anticodon-codon interactions, and interactions with enzymes. Anticodon modifications are important for proper decoding of mRNA. Since the genetic code is degenerate, anticodon modifications are necessary to properly decode mRNA. Particularly, the wobble position of the anticodon determines how the codons are read. For example, in eukaryotes an adenosine at position 34 of the anticodon can be converted to inosine. Inosine is a modification that is able to base-pair with cytosine, adenine, and uridine. Another commonly modified base in tRNA is the position adjacent to the anticodon. Position 37 is often hypermodified with bulky chemical modifications. These modifications prevent frameshifting and increase anticodon-codon binding stability through stacking interactions.
=== Names === Cyproheptadine is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française. The drug's DCITTooltip Denominazione Comune Italiana is ciproeptadina, while its BANMTooltip British Approved Name is cyproheptadine hydrochloride (as the hydrochloride salt) and its JANTooltip Japanese Accepted Name is cyproheptadine hydrochloride hydrate (as the hydrochloride hydrate form). Synonyms of cyproheptadine include Fl-5967, HSp-1229, Glutodina, Axoprol, and Dihexazin. The drug is sold under many brand names, but its major brand names are Periactin and to a lesser extent Peritol.
Sources: en.wikipedia.org
== Applications == The coupling of MS with LC systems is attractive because liquid chromatography can separate delicate and complex natural mixtures whose chemical composition needs to be well established, such as biological fluids, environmental samples, and drugs. Further, LC–MS has applications in volatile explosive residue analysis. Nowadays, LC–MS has become one of the most widely used chemical analysis techniques because more than 85% of natural chemical compounds are polar and thermally labile, and GC-MS cannot process these samples. As an example, HPLC–MS is regarded as the leading analytical technique for proteomics and pharmaceutical laboratories. Other important applications of LC–MS include the analysis of food, pesticides, and plant phenols.
Yaqout had also been linked to the timeshare vacation apartment scam of British gangster John "Goldfinger" Palmer (who was murdered in 2015). This scam cheated 20,000 customers out of their money which reached a figure of up to €400 million. It was reported that Yaqout was involved in cocaine trafficking alongside prominent figures of the Moroccan mafia, such as his cousin Naoufal Fassih and Ridouan Taghi. Yaqout was assassinated in his car in the neighbourhood of Las Petunias in San Pedro de Alcántara on 22 January 2019. At least one hitman was involved, riddling the drivers' side of Yaqout's Bentley with more than 20 bullets while he was waiting for an electric gate to open. He allegedly tried to escape the assassination by crawling onto the passenger side but was found dead halfway between the seats. He is buried in his hometown in Khouribga, Morocco. The Bouyakhrichan organisation are the main suspects of this assassination. Naoufal Fassih was alongside Taghi allegedly allied with the Iranian secret service and ordered to carry out gangland-style killings on enemies of the Iranian government who were hiding out on European soil.
where Da is the symbol for the unit dalton (also called the unified atomic mass unit, symbol u), and e is the elementary charge, which is the unit of electric charge in the system of atomic units. For example, the ion C7H72+ has a mass of 91 Da. Its charge number is +2, and hence its charge is 2e. The ion will be observed at 45.5 Th in a mass spectrum. The thomson allows for negative values for negatively charged ions. For example, the benzoate anion would be observed at −121 Th since the charge is −e.
Think tanks have been important allies for United States presidents since the Reagan administration, writing and suggesting policies to implement, and providing staff for the administration. For recent conservative presidents, think tanks such as The Heritage Foundation, the Hoover Institution, and the American Enterprise Institute (AEI) were closely associated with the Reagan administration. The George H. W. Bush administration worked closely with AEI, and the George W. Bush administration worked closely with AEI and the Hoover Institution. The Trump administration works closely with the Heritage Foundation. For recent liberal presidents, the Progressive Policy Institute and its parent the Democratic Leadership Council were closely associated with the Clinton administration, and the Center for American Progress was closely associated with the Obama and Biden administrations. Think tanks help shape both foreign and domestic policy. They receive funding from private donors, and members of private organizations. By 2013, the largest 21 think tanks in the US spent more than US$1 billion per year. Think tanks may feel more free to propose and debate controversial ideas than people within government. The progressive media watchdog Fairness and Accuracy in Reporting (FAIR) has identified the top 25 think tanks by media citations, noting that from 2006 to 2007 the number of citations declined 17%. The FAIR report reveals the ideological breakdown of the citations: 37% conservative, 47% centrist, and 16% liberal.
=== Migration of can components === In canning toxicology, migration is the movement of substances from the can itself into the contents. One toxic substance that can migrate is lead, which causes lead poisoning, but has been phased out of usage in cans since the 20th century. A newer concern is bisphenol A (BPA), a potential endocrine disruptor that is an ingredient in the epoxy commonly used to coat the inner surface of cans. Some cans are manufactured with a BPA-free enamel lining produced from plant oils and resins. In February 2018, the Can Manufacturers Institute, a trade association in the United States, surveyed the industry and reported that at least 90% of food cans no longer contained BPA.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.